MK-677 (IBUTAMOREN)

Growth Hormone SecretionResearch Only

Solid research foundation with consistent results across multiple human studies. The oral bioavailability and selective action make it particularly valuable for research applications.

Age-related research groups frequently employ ibutamoren in studies examining muscle wasting, bone density decline, and sleep disorders in older adults.

FDA Status

Research Only

Since Feb 2026

Evidence

Strong

Studies

18 total, 3 human

What is MK-677 (IBUTAMOREN)?

Often called a peptide despite being technically a small molecule, ibutamoren has gained attention for its ability to boost growth hormone levels through oral administration. Researchers study it primarily for its effects on muscle preservation, bone health, and sleep patterns in aging populations. Unlike injectable growth hormone, it works by triggering the body's own natural GH release mechanisms.

Ibutamoren essentially tricks the brain into thinking the body needs more growth hormone by activating the same receptor that responds to ghrelin, the 'hunger hormone.' When it binds to the GHS-R1a receptor in the pituitary gland, it triggers natural pulses of growth hormone release, which then cascade into increased IGF-1 production. This approach maintains the body's normal rhythm of GH secretion rather than providing a constant external supply.

What the Research Shows

The 18 studies include well-designed human trials with measurable endpoints, though the total number of human subjects remains relatively modest compared to established pharmaceuticals.